Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Vanda Therapy Helps the Blind Sleep, FDA Staff Says

Nov. 12 (Bloomberg) -- Vanda Pharmaceuticals Inc.’s experimental drug should be approved to regulate the circadian rhythms of blind people and help them sleep, a U.S. regulatory reviewer said. The shares jumped 96 percent.

The medicine, known as tasimelteon, is effective at synchronizing the body with a 24-hour cycle, Food and Drug Administration staff said today in a report ahead of a Nov. 14 meeting of agency advisers. The drugmaker climbed to $13.30 at the close in New York, its biggest increase since May 2009. The shares have more than quadrupled in the last 12 months.

No approved treatments exist for the condition called non-24-hour disorder, which affects as many as 95,000 totally blind people in the U.S, Vanda said. Most people have a master body clock that naturally runs longer than 24 hours and light resets the clock, according to the Rockville, Maryland-based company.

Patients with non-24-hour disorder now try the hormone melatonin with mixed results. Vanda studied its compound’s ability to “entrain” or modify circadian rhythms.

The FDA is expected to decide whether to approve tasimelteon, which Vanda has proposed calling Hetlioz, by Jan. 31. Vanda’s only FDA approved product, Fanapt for schizophrenia, is licensed to Novartis AG in the U.S.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.